SUPN - CIK 0001356576
The table below shows SUPERNUS PHARMACEUTICALS, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $66.52M | $30.60M | $38.40M | $49.13M | $4.30M | $36.20M |
| Capital expenditure | $0.00 | $327.00K | $248.00K | $278.00K | $851.00K | $1.51M |
| Investing cash flow | -$19.22M | $37.32M | -$51.62M | $239.78M | -$69.99M | -$71.44M |
| Dividends paid | - | - | - | - | - |
SUPERNUS PHARMACEUTICALS, INC. reported operating cash flow of $47.33M for fiscal year 2025. That is down 72.5% from $171.95M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $66.81M (FY 2016) to $47.33M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $9.12M | -$21.40M | $1.57M | $80.17M | -$22.03M | $2.25M |